Jonasch, E., Tannir, N. M., Hahn, A. W., Goswami, S., Msaouel, P., Shah, A. Y., Tidwell, R. S., Hwang, H., Wood, L. M., Syed, M., Solley, T., Fares, S., Lewis, L. S., Brooks, E., Bartell, H., George, D. J., Haas, N. B., Harrison, M. R., Hammers, H. J., Rini, B. I. (2026). A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps580